LC
AERI

Loews Corp’s Aerie Pharmaceuticals AERI Stock Holding History

Loews Corp’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,800
Closed -$309K – 100
2019
Q4 		$309K Sell
12,800
-7,895
-38% -$164K ﹤0.01% 71
2019
Q3 		$398K Buy
+20,695
New +$474K ﹤0.01% 68

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Loews Corp's AERI Position: Q1 2020 in Review

Loews Corp sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 12,800 shares — an estimated $309K sold.

Loews Corp first reported a position in AERI in Q3 2019 and held it in 2 quarters. The position peaked at $398K in Q3 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

  • Loews Corp reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Loews Corp sold 12,800 Aerie Pharmaceuticals shares in Q1 2020, an estimated $309K.
  • Loews Corp first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Loews Corp's Aerie Pharmaceuticals position peaked at $398K in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Loews Corp's 13F filing for Q1 2020, filed 12 May 2020.